Gene Therapy for Rare Disorders Europe will focus exclusively on how drug developers can progress gene therapies to market more effectively.
Incorporating insights from Pfizer, GSK, UniQure and the EMA, the 2017 meeting delved into the key clinical, manufacturing regulatory and reimbursement hurdles that need to be overcome to realize the commercial potential of gene therapies.
Join your peers to evaluate the latest case studies and lessons learned from the rapid progress of these advanced therapeutics in addressing the unmet need in the rare disease space. Practical takeaways will enable you to accelerate your development of marketable gene therapies.
Register your interest to be the first to see our 2018 program.
“I’ve gained a lot from this conference – it’s allowed us to think outside the company and get other people’s impressions and experiences and that will benefit the entire area and landscape. I look forward to many more of these meetings in the future.”
Sven Kili, VP, Head of Cell & Gene Therapy Development, GSK